Design and development of a bispecific antibody targeting BAFF and IL-17 for systemic lupus erythematosus treatment.

ABSTRACT:

Background

This study aimed to develop and evaluate a bispecific single-chain variable fragment (bsscFv) targeting B-cell activating factor (BAFF) and interleukin-17 (IL-17) for the treatment of systemic lupus erythematosus (SLE).

Methods

The bsscFv was engineered by linking single-chain variable fragments (scFvs) specific for BAFF and IL-17 with a flexible peptide linker. It was expressed in E. coli BL21 and purified using affinity chromatography. Binding affinities to BAFF and IL-17 were assessed by enzyme-linked immunosorbent assay (ELISA). In vitro neutralization assays were conducted using Raji and HT-29 cell cultures. In vivo therapeutic efficacy was evaluated in an MRL/lpr mouse model of SLE, with 10 mice per group. Statistical significance was determined using a Stud

SUBMITTER: Xin C 

PROVIDER: S-EPMC12482122 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature